Single-Cell Microdevice Isolates and Profiles Extracellular Vesicles over Weeks

Why It Matters

Connecting extracellular vesicles to their originating cells provides granular insight into tumor heterogeneity, informing drug‑resistance mechanisms and personalized therapy strategies.

Key Takeaways

• Sealed microwells culture single cells up to 19 days.
• Vesicles trapped per well, preventing cross‑contamination.
• Cell‑specific vesicle counts and protein profiles vary widely.
• Platform links vesicle signatures to individual cell behavior.
• Enables precision studies of cancer metastasis and drug response.

Pulse Analysis

Extracellular vesicles (EVs) have emerged as critical messengers in cancer, influencing metastasis, immune evasion, and therapeutic resistance. Traditional bulk isolation methods average signals across millions of cells, obscuring the nuanced behavior of individual contributors. While single‑vesicle techniques can dissect particle heterogeneity, they lack contextual information about the parent cell, and existing single‑cell platforms often suffer from short culture periods or fluidic mixing that blurs source attribution. This methodological gap has limited researchers’ ability to map dynamic cell‑to‑EV communication over biologically relevant timescales.

The newly reported microdevice addresses these challenges with a clever combination of oil‑sealed, RGD‑modified alginate microwells that maintain a sterile, nutrient‑rich microenvironment for single adherent cells. By physically restricting larger vesicles within each well, the system captures a complete secretion record without cross‑talk between neighboring cells. In proof‑of‑concept experiments, cancer cells cultured for nearly three weeks displayed divergent proliferation rates, and their isolated EVs exhibited wide variations in quantity, size distribution, and surface protein markers. These findings confirm that EV output is highly cell‑specific and not merely a function of cell density, providing a direct link between cellular phenotype and secreted cargo.

The implications extend far beyond basic biology. Researchers can now interrogate how individual tumor cells respond to drugs, evolve resistance, or interact with the microenvironment by tracking EV signatures longitudinally. Scaling the platform with automation could enable high‑throughput profiling of thousands of cells, accelerating biomarker discovery and informing precision‑medicine pipelines that prioritize patient‑specific cellular behavior over population averages. As the technology matures, integration with single‑cell RNA or protein assays could deliver a multimodal view of cellular heterogeneity, reshaping therapeutic development and clinical diagnostics.